Leukocyte News and Research

RSS

Researchers investigate why immune system is blunted after spinal cord injury

Mobility is a challenge for spinal cord injured patients. Infection is another. Adam Thrasher, assistant professor of health and human performance, says infection is the leading cause of death for people living with spinal cord injuries for two years or more.

4 Mar 2011

Dentists need to take a closer look at potential hazards of exposing patients to zinc

Dentists need to take a closer look at potential hazards of exposing patients to zinc, a common ingredient of many dental products, according to a report by Amar Patel, DDS, resident and colleagues at the University of Maryland Dental School in the March/April 2011 issue of the journal General Dentistry.

4 Mar 2011

Executioner enzyme may short circuit second form of cell death

An enzyme viewed as an executioner, because it can push cells to commit suicide, may actually short circuit a second form of cell death, researchers at Emory University School of Medicine have discovered.

4 Mar 2011

Affymetrix releases complete genotyping data set on its website

Affymetrix, Inc. today announced the release of a complete data set of 5 million variants on its website.

3 Mar 2011

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

Eisai announced today that results from the global Phase III clinical study "EMBRACE" will be published online in The Lancet.

3 Mar 2011

New breakthrough in immunological research

Immunological research at the University of Haifa, Israel, has made a new breakthrough, revealing a critical component in the "decision-making" process of white blood cells that play a role in the healing process from bacterial inflammation.

3 Mar 2011

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

3 Mar 2011

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

German researchers have found a significant association of IL28B genotypes to interferon-based antiviral treatment outcome, and to graft inflammation caused by hepatitis C virus (HCV). The study determined that the presence of G-allele serves as a marker for severe HCV-induced graft inflammation, as well as a predictor for unsuccessful treatment. Study findings—the largest to report on the role IL28B variants in a transplant cohort with recurrent HCV—are published in the March issue of Liver Transplantation, a journal of the American Association for the Study of Liver Diseases.

2 Mar 2011

Mathematical model predicts lifespan of stem cells

When patients receive a bone marrow transplant, they are getting a new population of hematopoietic stem cells. Fresh stem cells are needed when a patient is low on red blood cells, as in anemia, or white blood cells, which can be caused by cancer or even cancer treatments such as irradiation or chemotherapy. The problem is that a bone marrow transplant might not succeed because the transplanted stem cells don't live long enough or because they proliferate too well, leading to leukemia.

2 Mar 2011

New insight into HIV/AIDS

A paper published in the March 2011 print edition of the Journal of Clinical Investigation offers new insight into what prompts immunity to AIDS in sooty mangabeys, a natural host African monkey species.

2 Mar 2011

Vaccine-induced cellular immune responses against HIV-1 infection exert selective pressure on the virus

An AIDS vaccine tested in people, but found to be ineffective, influenced the genetic makeup of the virus that slipped past. The findings suggest new ideas for developing HIV vaccines.

2 Mar 2011

New research reveals how maternal antibodies block immune response to measles virus

New research that reveals how maternal antibodies block an immune response to the measles virus is a first step toward improving current childhood vaccination practices, scientists say.

1 Mar 2011

Cancer drug may help combat flu

Ever get a flu shot and still get the flu? If so, there's new hope for flu-free winters in the years to come thanks to a new discovery by researchers who found that a drug called DMXAA, originally developed as anti-tumor agent, enhances the ability of flu vaccines to ward off this deadly virus.

1 Mar 2011

PAH closely related to bone marrow abnormalities

Results from a study published in Blood, the Journal of the American Society of Hematology reveal a close relationship between pulmonary arterial hypertension (PAH)-exceedingly high blood pressure in the arteries carrying blood from the heart to the lungs-and abnormalities of the blood-forming cells in the bone marrow (known as myeloid abnormalities).

1 Mar 2011

Immunitor to present latest results from imm01 trial in tuberculosis patients at African conference

Immune Network Ltd. advises that Immunitor will present latest results from its imm01 clinical trial in tuberculosis patients in Abuja, Nigeria at the 18th Union TB and Lung Diseases Conference of the African Region, 2nd to 5th March, 2011.

28 Feb 2011

Study findings support therapeutic approach for common form of MS

In an effort to develop therapeutic remedies for multiple sclerosis, scientists debate two possible interventional approaches - but they're on opposite sides of the spectrum. Researchers at Wayne State University's School of Medicine, however, have reached a definitive conclusion as to which approach is correct, putting an end to a long-disputed issue.

24 Feb 2011

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 2 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.

24 Feb 2011

MD Anderson physician honored for impact on blood, marrow transplantation

The American Society for Blood and Marrow Transplantation has honored leader, innovator and educator Richard Champlin, M.D., with its Lifetime Achievement Award during the group's annual meeting Feb. 17-21.

23 Feb 2011

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.

22 Feb 2011

New research: Reovirus infected melanoma cells secrete proteins that can kill cancer

Reoviruses are successfully being used in clinical trials to treat patients with cancer. Not only does the virus cause cancer cells to die, it also forces them to release pro-inflammatory chemokines and cytokines, which in turn causes the patient's immune system to attack the disease.

21 Feb 2011

Leukocyte News and Research

Researchers investigate why immune system is blunted after spinal cord injury

Dentists need to take a closer look at potential hazards of exposing patients to zinc

Executioner enzyme may short circuit second form of cell death

Affymetrix releases complete genotyping data set on its website

Eisai announces publication of Halaven Phase III study results against breast cancer in The Lancet journal

New breakthrough in immunological research

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

Genetic variants determine severity of HCV-related graft disease and antiviral treatment response

Mathematical model predicts lifespan of stem cells

New insight into HIV/AIDS

Vaccine-induced cellular immune responses against HIV-1 infection exert selective pressure on the virus

New research reveals how maternal antibodies block immune response to measles virus

Cancer drug may help combat flu

PAH closely related to bone marrow abnormalities

Immunitor to present latest results from imm01 trial in tuberculosis patients at African conference

Study findings support therapeutic approach for common form of MS

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

MD Anderson physician honored for impact on blood, marrow transplantation

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

New research: Reovirus infected melanoma cells secrete proteins that can kill cancer

Immunology eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News